









Markets
/
Stocks
/
nasdaq-bmra
/

Biomerica Inc

BMRA

1.985USD

-0.125-5.92%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

13.63MMarket Cap

LossP/E TTM



Biomerica Inc

1.985

-0.125-5.92%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biomerica Inc

Currency: USD Updated: 2026-03-27

Key Insights

Biomerica Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 153 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biomerica Inc's Score

Industry at a Glance

Industry Ranking

153 / 208

Overall Ranking

443 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Biomerica Inc Highlights

StrengthsRisks

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.31M.

Overvalued

The company’s latest PE is -1.28, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 21.13K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.18.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Biomerica Inc is 7.13, ranking 83 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.21M, representing a year-over-year decrease of 26.04%, while its net profit experienced a year-over-year decrease of 38.95%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

9.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.62

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.93

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Biomerica Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Biomerica Inc is 7.74, ranking 63 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.28, which is -55.67% below the recent high of -0.57 and -6563.00% above the recent low of -85.20.

Score

Industry at a Glance

Previous score

7.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 153/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for Biomerica Inc. The Healthcare Equipment & Supplies industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Biomerica Inc is 3.70, ranking 197 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.20 and the support level at 1.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.90

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.026

Neutral

RSI(14)

42.835

Neutral

STOCH(KDJ)(9,3,3)

41.495

Sell

ATR(14)

0.135

Low Volatility

CCI(14)

-81.988

Neutral

Williams %R

78.571

Sell

TRIX(12,20)

-0.129

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.114

Sell

MA10

2.106

Sell

MA20

2.071

Sell

MA50

2.220

Sell

MA100

2.352

Sell

MA200

2.731

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Biomerica Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 11.10%, representing a quarter-over-quarter decrease of 11.37%. The largest institutional shareholder is The Vanguard, holding a total of 21.13K shares, representing 0.70% of shares outstanding, with 24.10% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Irani (Zackary S)

219.13K

+31.51%

Barbieri (Allen)

67.29K

+80.44%

Lu (Gary)

64.53K

+163.05%

Moatazedi (David)

41.25K

+94.12%

Chin (Eric)

10.00K

Emerson (Jane)

30.13K

The Vanguard Group, Inc.

Star Investors

21.13K

BlackRock Institutional Trust Company, N.A.

18.64K

Geode Capital Management, L.L.C.

20.98K

-3.14%

DRW Securities, LLC

10.39K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biomerica Inc is 2.65, ranking 149 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.21. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.